Denali Therapeutics Inc. — Director's Dealing 2018

Oct 3, 2018

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Denali Therapeutics Inc. (DNLI)
CIK: 0001714899
Period of Report: 2018-10-02

Reporting Person: Schuth Alexander O. (COO and Secretary)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2018-10-02	Common Stock	M	1184	$5.28	Acquired	7102	Direct
2018-10-02	Common Stock	M	5859	$9.60	Acquired	12961	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2018-10-02	Stock Option (right to buy)	$5.28	M	1184	Disposed	2027-03-07	Common Stock (1184)	Direct
2018-10-02	Stock Option (right to buy)	$9.60	M	5859	Disposed	2027-08-21	Common Stock (5859)	Direct

Holdings (Non-Derivative)

Security	Shares	Ownership
Common Stock	685089	Indirect

Footnotes

F1: The shares are held of record by the Schuth Family Trust, for which the Reporting Person serves as trustee.

F2: 25% of the shares subject to the option vested on March 8, 2018 and an additional 1/48 of the shares vest monthly thereafter.

F3: 25% of the shares subject to the option vested on August 22, 2018 and an additional 1/48 of the shares vest monthly thereafter.